Press Release Source: Endovasc Ltd., Inc.
Endovasc Being Represented By Famous Trial Attorney
Friday September 13, 6:00 am ET
MONTGOMERY, TX--(INTERNET WIRE)--Sep 13, 2002 -- Endovasc Ltd., Inc. (OTC BB:ENVC.OB - News) announced today that the Houston law firms of O'Quinn, Laminack & Pirtle, with lead attorney John M. O'Quinn, and Christian, Wukoson, Smith & Jewell, with lead attorney James W. "Wes" Christian, have accepted the company's case for damages resulting from what the company believes has been a manipulation of its stock. John O'Quinn was named one of the Nation's Top 10 Litigators and one of the 100 Most Influential Lawyers in America by the National Law Journal.
ADVERTISEMENT
John O'Quinn and James W. Wes Christian represent several other bulletin board companies in their claims for damages resulting from alleged SEC 10b-5 violations, stock manipulation, and fraudulent misrepresentation by alleged "investors" whose intent allegedly was to drive down a company's stock price through short-selling and receive a much greater amount of the company's shares when converting from preferred stock, debenture, or other convertible provision in a financing deal with the bulletin board company.
"We have received a patent and exclusive licensing rights for nicotine field use in angiogenesis and vasculogenesis, and can now fully negotiate sublicenses, distribution and other rights," said Dr. David Summers, Chairman and CEO of Endovasc. "Recent trials using our treatment have shown that test animals with artificially induced coronary artery constriction grew new blood vessels to replace the lost blood vessel supply to the heart," added Dr. Summers, "so we hope that help for humans whose hearts have been damaged from years of smoking will be available soon."
"Endovasc was looking forward to pursuing its business plan and further development of its groundbreaking products when its stock price, we feel, was decimated by a group of 'investors' who apparently had other motives," said Attorney Wes Christian, who also said he has just completed his preliminary investigation of the company's misfortune with this financial group. "John O'Quinn has spent his career taking care of bullies," added Christian.
Endovasc Ltd., Inc., established in 1996, is a biotechnology company focused in the area of cardiovascular disease, pioneering drug delivery technology designed to deliver and release drugs to their intended targets in an efficient and controlled manner. The Company's pipeline of products and processes include: Liprostin(TM), ANGIOGENIX(TM) (Nicotine Receptor Agonist), PROStent(TM) stent-coating technology, and a biodegradable resorbable stent prosthesis.
The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release. For more information about Endovasc, please visit www.endovasc.com . (Investor questions and requests for materials can be submitted online.)
Contact Information: Investor Relations, Endovasc Ltd., Inc., 15001 Walden Road, Ste. #108, Montgomery, TX 77356, Phone: 936-448-2222, Fax: 936-582-2250, InvestorRelations@endovasc.com.
Contact:
Company: Endovasc
Title: Investor Relations
Voice: 936-448-2222
Fax: 936-582-2250
Email: InvestorRelations@endovasc.com
-------------------------------------------------------------------------------- |
